"Torsades de Pointes" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant form of polymorphic ventricular tachycardia that is characterized by HEART RATE between 200 and 250 beats per minute, and QRS complexes with changing amplitude and twisting of the points. The term also describes the syndrome of tachycardia with prolonged ventricular repolarization, long QT intervals exceeding 500 milliseconds or BRADYCARDIA. Torsades de pointes may be self-limited or may progress to VENTRICULAR FIBRILLATION.
| Descriptor ID |
D016171
|
| MeSH Number(s) |
C14.280.067.845.940.700 C14.280.123.875.940.700 C23.550.073.845.940.700
|
| Concept/Terms |
Torsades de Pointes- Torsades de Pointes
- Pointes, Torsades de
- de Pointes, Torsades
- Torsade de Pointes
- Pointes, Torsade de
- de Pointes, Torsade
|
Below are MeSH descriptors whose meaning is more general than "Torsades de Pointes".
Below are MeSH descriptors whose meaning is more specific than "Torsades de Pointes".
This graph shows the total number of publications written about "Torsades de Pointes" by people in this website by year, and whether "Torsades de Pointes" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 1 | 0 | 1 |
| 2008 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2012 | 1 | 0 | 1 |
| 2020 | 1 | 0 | 1 |
| 2024 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Torsades de Pointes" by people in Profiles.
-
A Calculated Risk: Evaluation of QTc Drug-Drug Interaction (DDI) Clinical Decision Support (CDS) Alerts and Performance of the Tisdale Risk Score Calculator. Drug Saf. 2024 Dec; 47(12):1235-1243.
-
Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis. JAMA Netw Open. 2024 Apr 01; 7(4):e248732.
-
Use of high throughput ion channel profiling and statistical modeling to predict off-target arrhythmia risk - One pharma's experience and perspective. J Pharmacol Toxicol Methods. 2022 Nov-Dec; 118:107213.
-
Characterization of a high throughput human stem cell cardiomyocyte assay to predict drug-induced changes in clinical electrocardiogram parameters. Eur J Pharmacol. 2021 Dec 05; 912:174584.
-
Use of QT Prolonging Medications by Hemodialysis Patients and Individuals Without End-Stage Kidney Disease. J Am Heart Assoc. 2020 07 07; 9(13):e015969.
-
Loperamide associated torsades de pointes, in the setting of complete heart block at marginally supratherapeutic dosing (20mg/day). Clin Toxicol (Phila). 2019 11; 57(11):1123-1124.
-
Cardiac safety assays. Curr Opin Pharmacol. 2014 Apr; 15:16-21.
-
T-type calcium current contributes to escape automaticity and governs the occurrence of lethal arrhythmias after atrioventricular block in mice. Circ Arrhythm Electrophysiol. 2013 Aug; 6(4):799-808.
-
Torsades de pointes and prolonged QT syndrome in Takotsubo cardiomyopathy. J Cardiovasc Med (Hagerstown). 2012 Aug; 13(8):536-40.
-
Levofloxacin-induced torsades de pointes. Tex Heart Inst J. 2010; 37(2):216-7.